Candida auris

This first of a 2-part report on new guideline from the European Confederation for Medical Mycology (ECMM) summarizes diagnostic considerations; with part 2 describing recommended treatments.

Oliver A Cornely shares guidance on tackling Candida infections in an evolving landscape, including rising resistance and taxonomic changes.

Koos Korsten, MD, PhD, MSc discusses how clinical context, including prevalence and outbreak situations, influences the choice between PCR and culture-based diagnostics for Candidozyma auris.

Carlien Pohl-Albertyn's, PhD research highlights the role of the South African brown locust in the transmission and survival of the emerging pathogen Candida auris.

Deborah Birx, MD, and Amy Carenza, BBA, highlight the targeting of multidrug-resistant organisms and tracking of infection trends without increasing staffing needs.

ActivePure’s Deborah Birx, MD, and Amy Carenza, BBA, discuss their study showing a 99% reduction in fungal colony-forming units, 98% reduction in aerobic bacteria, and a 66% decrease in C auris.

Basilea Pharmaceutica says its investigational therapy, fosmanogepix, is being studied for candidemia and invasive candidiasis.

In the second installment of a 3-part series on long-acting injectables related to various infections, Caitlin Soto, PharmD, BCIDP, provides insights on using rezafungin for invasive candidiasis.

The results were presented at the Society for Healthcare Epidemiology of America (SHEA) conference, highlighting this first documented case of C auris moving from an adult to a pediatric unit within the state.

The fungal infection includes 4 patients, but so far no deaths are associated with it.

Candida auris fungal infections increased 95% in 2021, and drug-resistant cases are continuing to spread across the US.